Clinical trialNCT03029585TerminatedPhase 2Interventional

Phase II Study of Intraperitoneal NanoPac® in Patients With Ovarian Cancer

SponsorNanOlogy, LLCEnrollment10Ovarian Carcinoma

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This study will evaluate NanoPac® administered intraperitoneally (IP) immediately post-cytoreductive surgery, followed by standard of care (SOC) intravenous (IV) chemotherapy, in women with ovarian cancer. The study will compare IP NanoPac® (plus IV chemotherapy) with SOC IV chemotherapy alone.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

Gere diZerega, MD
US Biotest, Inc./NanOlogy, LLC
Study Chair
clinicaltrials.gov ↗
Joan Walker, MD
University of Oklahoma
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

7 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

University of Chicago
Chicago, Illinois, United States
Greater Baltimore Medical Center
Baltimore, Maryland, United States
University of Minnesota
Minneapolis, Minnesota, United States
Suny Downstate
Brooklyn, New York, United States
Magee-Womens Hospital of Upmc
Pittsburgh, Pennsylvania, United States
Women & Infants Hospital of Rhode Island
Providence, Rhode Island, United States
University of Texas Southwestern
Dallas, Texas, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

NanoPac® 100 mg/m2NanoPac® 200 mg/m2NanoPac® 300 mg/m2NanoPac® 400 mg/m2Standard of Care Intravenous Chemotherapy

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 19 Apr 2017
Primary completion: 4 Nov 2019
Completion: 4 Nov 2019
Last update posted: 27 Apr 2021
Registered enrollment: 10
Registry id: NCT03029585

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.